Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review
出版年份 2022 全文链接
标题
Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review
作者
关键词
-
出版物
Current Pain and Headache Reports
Volume 26, Issue 10, Pages 783-794
出版商
Springer Science and Business Media LLC
发表日期
2022-09-05
DOI
10.1007/s11916-022-01077-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine
- (2022) Laszlo Mechtler et al. Frontiers in Neurology
- Myocardial infarction in a patient with migraine and triptan overuse treated with anti-CGRP receptor monoclonal antibody: a case report
- (2022) I. Cetta et al. JOURNAL OF NEUROLOGY
- Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial
- (2021) Messoud Ashina et al. EUROPEAN JOURNAL OF NEUROLOGY
- Hypertension: A new safety risk for patients treated with erenumab
- (2021) Suprat Saely et al. HEADACHE
- Real‐world efficacy, tolerability, and safety of ubrogepant
- (2021) Chia‐Chun Chiang et al. HEADACHE
- Efficacy and Tolerability of Calcitonin Gene-Related Peptide Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine
- (2021) Fred Cohen et al. PAIN MEDICINE
- Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
- (2021) David Kudrow et al. BMC Neurology
- Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study
- (2021) Abhijeet Jakate et al. HEADACHE
- Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke‐like episodes syndrome: A case report
- (2021) Steffen Naegel et al. HEADACHE
- Long‐term efficacy and safety during open‐label erenumab treatment in Japanese patients with episodic migraine
- (2021) Fumihiko Sakai et al. HEADACHE
- Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
- (2021) Fabrizio Vernieri et al. JOURNAL OF HEADACHE AND PAIN
- Long-Term Efficacy and Safety of Erenumab
- (2021) Peter J. Goadsby et al. NEUROLOGY
- Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review
- (2021) Andrew M. Blumenfeld et al. Pain and Therapy
- Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon
- (2021) Ilana D. Breen et al. JAMA Network Open
- Refractory migraine profile in CGRP‐monoclonal antibodies scenario
- (2021) Marcello Silvestro et al. ACTA NEUROLOGICA SCANDINAVICA
- Reversible cerebral vasoconstriction syndrome developing after an erenumab injection for migraine prevention
- (2021) Todd D Rozen et al. CEPHALALGIA
- Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial
- (2021) Todd J Schwedt et al. CEPHALALGIA
- Treatment with the monoclonal calcitonin gene‐related peptide receptor antibody erenumab: A real‐life study
- (2021) Simone de Vries Lentsch et al. EUROPEAN JOURNAL OF NEUROLOGY
- Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
- (2021) Piero Barbanti et al. HEADACHE
- Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study
- (2021) Takao Takeshima et al. HEADACHE
- Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study
- (2021) Messoud Ashina et al. JOURNAL OF HEADACHE AND PAIN
- MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention
- (2021) Robert Belvís et al. JOURNAL OF HEADACHE AND PAIN
- Atogepant for the Preventive Treatment of Migraine
- (2021) Jessica Ailani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
- (2021) Peter McAllister et al. JOURNAL OF HEADACHE AND PAIN
- Inflammatory complications of CGRP monoclonal antibodies: a case series
- (2021) Jason C. Ray et al. JOURNAL OF HEADACHE AND PAIN
- Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany
- (2021) Andreas Straube et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes
- (2021) Jean Schoenen et al. Frontiers in Neurology
- Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
- (2021) Raffaele Ornello et al. Frontiers in Neurology
- Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
- (2020) Messoud Ashina et al. CEPHALALGIA
- Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy
- (2020) Kathleen Mullin et al. NEUROLOGY
- Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
- (2020) Stewart J Tepper et al. CEPHALALGIA
- Dual Therapy With Anti‐CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?
- (2020) Lanfranco Pellesi et al. HEADACHE
- Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants
- (2020) Wendy Ankrom et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy
- (2020) Raffaele Ornello et al. JOURNAL OF HEADACHE AND PAIN
- Efficacy and safety of eptinezumab in patients with chronic migraine
- (2020) Richard B. Lipton et al. NEUROLOGY
- Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study
- (2020) Bianca Raffaelli et al. Frontiers in Neurology
- Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice
- (2020) Inge A. Mulder et al. ANNALS OF NEUROLOGY
- The potential danger of blocking CGRP for treating migraine in CADASIL patients
- (2020) Irene de Boer et al. CEPHALALGIA
- Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review
- (2020) Rami Burstein et al. HEADACHE
- Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience
- (2020) Antonio Russo et al. JOURNAL OF HEADACHE AND PAIN
- A prospective real-world analysis of erenumab in refractory chronic migraine
- (2020) Giorgio Lambru et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab in highly therapy-refractory migraine patients: First German real-world evidence
- (2020) Armin Scheffler et al. JOURNAL OF HEADACHE AND PAIN
- Real-world effectiveness and tolerability of erenumab: A retrospective cohort study
- (2020) Saad Kanaan et al. CEPHALALGIA
- Adverse effects of erenumab on cerebral proliferative angiopathy: A case report
- (2020) Laura L Lehman et al. CEPHALALGIA
- Erenumab in Chronic Migraine: An Australian Experience
- (2020) Shuli Cheng et al. HEADACHE
- Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine
- (2020) Jennifer Robblee et al. HEADACHE
- Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial
- (2020) Wim M Mulleners et al. LANCET NEUROLOGY
- Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial
- (2020) Peter J Goadsby et al. LANCET NEUROLOGY
- LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF FREMANEZUMAB IN MIGRAINE: A RANDOMIZED STUDY
- (2020) Peter J. Goadsby et al. NEUROLOGY
- Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
- (2020) Robert Croop et al. LANCET
- European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
- (2019) Simona Sacco et al. JOURNAL OF HEADACHE AND PAIN
- Erenumab: from scientific evidence to clinical practice—the first Italian real-life data
- (2019) Piero Barbanti et al. NEUROLOGICAL SCIENCES
- Ischemic Stroke Associated With Calcitonin Gene-Related Peptide Inhibitor Therapy for Migraine: A Case Report
- (2019) Stephen Aradi et al. Journal of Stroke & Cerebrovascular Diseases
- Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
- (2019) Robert Croop et al. LANCET
- Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine
- (2019) Richard B. Lipton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial
- (2019) Michel D Ferrari et al. LANCET
- Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine
- (2019) Richard B. Lipton et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Ubrogepant for the Treatment of Migraine
- (2019) David W. Dodick et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
- (2018) Vladimir Skljarevski et al. CEPHALALGIA
- ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
- (2018) David W Dodick et al. CEPHALALGIA
- Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
- (2018) David W. Dodick et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Evaluation of Galcanezumab for the Prevention of Episodic Migraine
- (2018) Virginia L. Stauffer et al. JAMA Neurology
- Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
- (2018) Uwe Reuter et al. LANCET
- Galcanezumab in chronic migraine
- (2018) Holland C. Detke et al. NEUROLOGY
- Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
- (2017) Stewart Tepper et al. LANCET NEUROLOGY
- Fremanezumab for the Preventive Treatment of Chronic Migraine
- (2017) Stephen D. Silberstein et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Controlled Trial of Erenumab for Episodic Migraine
- (2017) Peter J. Goadsby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Calcitonin Gene-Related Peptide: Physiology and Pathophysiology
- (2014) F. A. Russell et al. PHYSIOLOGICAL REVIEWS
- Antiinflammatory Activities of CGRP Modulating Innate Immune Responses in Health and Disease
- (2013) Bernhard Holzmann CURRENT PROTEIN & PEPTIDE SCIENCE
- Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura
- (2010) Jakob Møller Hansen et al. CEPHALALGIA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More